Occupation is patient/consumer.The patient's meter and test strips were provided for investigation where they were tested using retention controls.Testing results (qc range = 2.4 - 3.6 inr): qc 1: 3.1 inr, qc 2: 3.1 inr, qc 3: 3.1 inr.The obtained qc values were in the allowed range of the used combination strip lot - qc lot.All measurements were without error messages.The results alleged by the customer were observed in the meter¿s patient result memory.On a regular basis, coaguchek strips of lots currently valid in the market are tested as part of routine retention testing and results have passed the internal inspection.Per product labeling, "coaguchek uses human recombinant thromboplastin.Therefore, the comparability to other human recombinant thromboplastins is best, whereas higher deviations can occur with other thromboplastins.However, those higher differences between thromboplastins of different (rabbit, bovine based) origin are not a coaguchek specific issue.Similar differences can be observed when a human recombinant thromboplastin-based laboratory method is compared against several other (rabbit, bovine-based) laboratory methods." the investigation did not identify a product problem.The cause of the event could not be determined.
|
There was an allegation of questionable results from coaguchek xs meter serial number (b)(4) compared to a laboratory result using an unknown method.At 03:45 pm, the meter result was greater than 8.0 inr.The result was reported to patient¿s doctor and the doctor withheld the patient¿s coumadin for the night and told the patient to go hospital.The patient went to the emergency room and had blood drawn.At 06:00 pm, the laboratory result was 4.4 inr.The patient did not receive treatment based on her inr while at the hospital.The patient's therapeutic range is 2.0-3.0 inr.The patient¿s testing frequency is once every 1-2 weeks.
|